Oncology is a field of medicine that is focused on the treatment, prevention and diagnosis of cancer. Under this field is genitourinary oncology, a branch that is focused on cancer found in the reproductive system and the urinary system of women and men. The most common types of cancer under this branch include kidney, bladder and prostate cancer, which commonly occur in people aged 55 and above. We discuss them below.
This cancer is often diagnosed when an individual undergoes a test such as an MRI, a CT scan or an ultrasound for illness or pain, including back pain. Men are twice as likely to have this type of cancer in comparison with women. Estimates show that roughly 75,000 kidney cancer cases will be diagnosed this year in the United States.
This is the fourth most common type of cancer in men in the United States. It mostly occurs in people aged between 64 and 74, with projections from the American Cancer Society showing that more than 80,000 individuals will be diagnosed with bladder cancer this year. While men are three times as likely to be diagnosed with bladder cancer, women diagnosed with this type of cancer later in life usually have a worse prognosis.
The most common symptom of this particular cancer is blood in the urine, while a burning sensation or pain while urinating is a less common sign. This is because it also signals a urinary tract infection, which women are more likely to get.
This is the second most common cancer in men, after melanoma. Estimates show that about 250,000 people in America are expected to receive a prostate cancer diagnosis in 2021.
One in every eight men develop prostate cancer during their lifetime, but most of them don’t succumb to the disease. Over 3 million men living in the U.S. have been diagnosed with prostate cancer at some point in their lives.
Arya Khatiwoda, a urologist with the College of Osteopathic Medicine, Michigan State University, states that it’s important for men to undergo a prostate-specific antigen blood test and a prostate exam yearly after the age of 50. Khatiwoda notes that an annual test and exam is the best way to detect prostate cancer in its early stages.
Immunotherapy is the most common treatment used to treat kidney cancer and bladder cancer while radiation and/or surgery are commonly used to prostate cancer.
Everyone is advised to undergo annual checkups and tests as this will improve their chances of survival if diagnosed with the aforementioned cancers, especially given that entities such as Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are advancing the field of bladder cancer treatment by creating optics systems that make it easier for surgical oncologists to target malignant tissues during procedures.
NOTE TO INVESTORS: The latest news and updates relating to Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) are available in the company’s newsroom at https://ibn.fm/IMEXF
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.